Compare · LEGN vs ONCY
LEGN vs ONCY
Side-by-side comparison of Legend Biotech Corporation (LEGN) and Oncolytics Biotech Inc. (ONCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LEGN and ONCY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LEGN is the larger of the two at $3.85B, about 53.6x ONCY ($71.8M).
- Over the past year, LEGN is down 42.3% and ONCY is down 57.7% - LEGN leads by 15.4 points.
- LEGN has been more active in the news (17 items in the past 4 weeks vs 12 for ONCY).
- LEGN has more recent analyst coverage (25 ratings vs 2 for ONCY).
- Company
- Legend Biotech Corporation
- Oncolytics Biotech Inc.
- Price
- $18.45-6.72%
- $0.50-9.19%
- Market cap
- $3.85B
- $71.8M
- 1M return
- +4.95%
- -35.19%
- 1Y return
- -42.28%
- -57.70%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 17
- 12
- Recent ratings
- 25
- 2
Legend Biotech Corporation
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, it is developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL and targeting B-cell maturation antigen for the treatment of MM, which are currently in an investigator-initiated Phase 1 clinical trial in China. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Latest LEGN
- SEC Form 6-K filed by Legend Biotech Corporation
- Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
- SEC Form 6-K filed by Legend Biotech Corporation
- SEC Form S-8 filed by Legend Biotech Corporation
- Director Sanders Corazon (Corsee) D. sold $258,920 worth of Ordinary Shares (27,370 units at $9.46), decreasing direct ownership by 34% to 52,731 units (SEC Form 4)
- Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
- SEC Form 144 filed by Legend Biotech Corporation
- Director Heyman Tomas J. was granted 20,986 units of Ordinary Shares, increasing direct ownership by 64% to 53,720 units (SEC Form 4)
- Director Casey Patrick John was granted 20,986 units of Ordinary Shares, increasing direct ownership by 43% to 69,590 units (SEC Form 4)
- Director Mao Li was granted 20,986 units of Ordinary Shares, increasing direct ownership by 47% to 65,316 units (SEC Form 4)
Latest ONCY
- SEC Form 8-K filed by Oncolytics Biotech Inc.
- Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- SEC Form 8-K filed by Oncolytics Biotech Inc.
- Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
- SEC Form DEFA14A filed by Oncolytics Biotech Inc.
- SEC Form DEF 14A filed by Oncolytics Biotech Inc.
- Oncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
- Oncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits